Where can I buy shares of clsn?
Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here.
What does clsn stand for?
Celsion Corporation (CLSN), an oncology drug-development company, announces that Michael Tardugno, Chairman, President and Chief Executive Officer and Khursheed Anwer, Executive Vice President and Chief Scientific Officer will present at the Chardan 3rd Annual Genetic Medicines Conference on...
Where can I buy Celsion shares?
Shares of CLSN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Celsion's stock price today?
What is the short interest on Celsion stock?
Celsion saw a decline in short interest in January. As of January 15th, there was short interest totaling 993,900 shares, a decline of 15.1% from the December 31st total of 1,170,000 shares. Based on an average daily volume of 738,600 shares, the short-interest ratio is currently 1.3 days. View Celsion's Short Interest.
Is Clsn stock a good buy?
Celsion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
What does celsion Corporation do?
Celsion Corporation is a fully integrated oncology company with a high-potential portfolio of innovative cancer treatments. With platform technologies in chemotherapy and gene-mediated immunotherapy, and RNAi engineered to enhance the clinical benefits of proven agents, Celsion's mission is transformational.
Will Clsn go up?
The 2 analysts offering 12-month price forecasts for Celsion Corp have a median target of 30.50, with a high estimate of 45.00 and a low estimate of 16.00. The median estimate represents a +1,352.38% increase from the last price of 2.10.
What is ThermoDox?
Delivers 25 times more doxorubicin into tumors ThermoDox, delivered by IV infusion, is designed to be used in combination with heat-based treatments, such as radiofrequency thermal ablation (RFA), microwave hyperthermia, or high-intensity focused ultrasound (HIFU).
Should I buy or sell Celsion stock right now?
2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celsion in the last year. There are currently 2 buy rati...
What is Celsion's stock price forecast for 2022?
2 analysts have issued twelve-month price targets for Celsion's stock. Their forecasts range from $16.00 to $16.00. On average, they expect Celsion...
How has Celsion's stock performed in 2022?
Celsion's stock was trading at $8.10 on January 1st, 2022. Since then, CLSN shares have decreased by 73.1% and is now trading at $2.18. View the b...
When is Celsion's next earnings date?
Celsion is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022. View our earnings forecast for Celsion .
How were Celsion's earnings last quarter?
Celsion Co. (NASDAQ:CLSN) announced its quarterly earnings data on Monday, May, 16th. The biotechnology company reported ($1.82) earnings per share...
When did Celsion's stock split? How did Celsion's stock split work?
Celsion shares reverse split before market open on Tuesday, March 1st 2022. The 1-15 reverse split was announced on Tuesday, March 1st 2022. The nu...
Who are Celsion's key executives?
Celsion's management team includes the following people: Mr. Michael H. Tardugno , Exec. Chairman, Pres & CEO (Age 71, Pay $1.01M) Mr. Jeffrey W...
Who are some of Celsion's key competitors?
Some companies that are related to Celsion include InflaRx (IFRX) , Lumos Pharma (LUMO) , LifeVantage (LFVN) , Oncternal Therapeutics (ONCT) ,...
What other stocks do shareholders of Celsion own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Celsion investors own include Zosano Pharma (ZSAN) , Sorr...
How much does Celsion make?
What is Celsion Corp?
How much money does Celsion make? Celsion has a market capitalization of $90.89 million and generates $500,000.00 in revenue each year. The biotechnology company earns $-21,480,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis.
What is the P/E ratio of Celsion?
Celsion Corp . is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.
When did Celsion reverse split?
The P/E ratio of Celsion is -2.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Is there enough data for Celsion?
Celsion shares reverse split on the morning of Tuesday, May 30th 2017. The 1-14 reverse split was announced on Friday, May 26th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, May 26th 2017.
Does Celsion have a long track record of dividend growth?
There is not enough analysis data for Celsion.
How does MarketBeat calculate stock ratings?
Celsion does not have a long track record of dividend growth.
What does the blue line on the chart below mean?
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Does MarketBeat like Celsion?
The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
How much money did Celsion raise in 2021?
MarketBeat users like Celsion stock more than the stock of other Medical companies. 70.90% of MarketBeat users gave Celsion an outperform vote while medical companies recieve an average of 67.30% outperform votes by MarketBeat users.
Who is the chief science officer of Celsion?
Application Approval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program, Celsion has raised over $14 million in Non-Dilutive Capital LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, today announced it was notified by the New Jersey Economic Developmen
Is Celsion a phase 2 company?
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that Khursheed Anwer, Ph.D., executive vice president and chief science officer, will be making a presentation on the company’s GEN-1 interleukin 12 (IL-12) immunotherapy program at the Cytokine-Based Cancer Im
What is Celsion Corp?
LAWRENCEVILLE, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine development program, and the hiring of a veteran clinical trial project manager for its Phase II GEN-1 immunotherapy study in advanced ovarian cancer. These changes all are effective immediately and are as fol
Does market cap include convertible securities?
Celsion Corp is active in the biotechnology sector. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in a clinical trial for the treatment of primary liver cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.